Average Insider

Where insiders trade, we follow

$NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Healthcare
Sector
Biotechnology
Industry
Alon Ben-Noon
CEO
17
Employees
$0.70
Current Price
$26.39M
Market Cap
52W Low$0.63
Current$0.704.0% above low, 96.0% below high
52W High$2.52

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys22$400,000.00500,000All Buys
Sells00--
2 weeksBuys22$400,000.00500,000All Buys
Sells00--
1 monthBuys22$400,000.00500,000All Buys
Sells00--
2 monthsBuys22$400,000.00500,000All Buys
Sells00--
3 monthsBuys22$400,000.00500,000All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jun 16, 2026
Eisenberg Or
Chief Financial Officer
Purchase250,000$0.80$200,000.00View Details
Jun 16, 2026
Ben-Noon Alon
Chief Executive Officer
Purchase250,000$0.80$200,000.00View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Apr 6, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 25, 2026
EPS
Estimated-$0.07
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.5.2